WallStreetZenWallStreetZen

NASDAQ: ABUS
Arbutus Biopharma Revenue

OverviewForecastEarningsRevenue
DividendOwnership
Arbutus Biopharma revenue was $14.61M for the trailing 12 months ending Sep 30, 2025, with N/A growth year over year. Quarterly revenue for the quarter (Q3 2025) ending on Sep 30, 2025 was $529.0k, down 95.1% from last quarter. For the last reported fiscal year 2024 ending Dec 31, 2024, ABUS annual revenue was $6.2M, with -66% growth year-over-year.

ABUS past revenue growth

How has ABUS's revenue growth performed historically?

Company
116.64%
Industry
284.61%
Market
22.91%
ABUS's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Industry Performance
ABUS's revenue has grown faster... subscribe to Premium to read more.
Revenue Growth vs Market Performance
ABUS's revenue growth is accelerating... subscribe to Premium to read more.
Accelerating Revenue Growth Performance

ABUS revenue history

Current Revenue
$14.6M
Current Earnings
-$42.3M
Current Profit Margin
-289.4%

Be the first to know when ABUS announces revenue.

ABUS Revenue History By Year

ABUS Yearly RevenueABUS RevenueABUS ChangeABUS Revenue Growth
2024-12-31$6.17M-$11.97M-65.98%
2023-12-31$18.14M-$20.88M-53.51%
2022-12-31$39.02M$28.03M+255.11%
2021-12-31$10.99M$4.07M+58.92%
2020-12-31$6.91M$903.00k+15.02%
2019-12-31$6.01M$66.00k+1.11%
2018-12-31$5.95M-$4.76M-44.44%
2017-12-31$10.70M$9.21M+617.64%
2016-12-31$1.49M-$21.79M-93.59%
2015-12-31$23.28M$8.32M+55.66%
2014-12-31$14.95M-$512.00k-3.31%
2013-12-31$15.47M$1.36M+9.64%
2012-12-31$14.11M-$2.71M-16.10%
2011-12-31$16.81M-$4.54M-21.27%
2010-12-31$21.35M$6.93M+48.00%
2009-12-31$14.43M$2.70M+22.99%
2008-12-31$11.73MN/AN/A

1 of 2

Arbutus Biopharma Revenue FAQ

What was ABUS's revenue last quarter?

On Invalid Date, Arbutus Biopharma (NASDAQ: ABUS) reported Q3 2025 revenue of $529.00 thousand up 60.49% year over year. In the same quarter last year, Arbutus Biopharma's revenue was $1.34 million.

What was Arbutus Biopharma's revenue in 2024?

Arbutus Biopharma's annual revenue for the twelve months ending Dec 31, 2024 was $6.17 million, a 65.98% decrease year over year.

How much does Arbutus Biopharma make in a day?

Based on Arbutus Biopharma annual revenue for the past five years, ABUS makes an average of $44,511.23 per day.

What was Arbutus Biopharma's annual revenue growth in the past year?

As of Q4 2025, Arbutus Biopharma's revenue has grown 116.64% year over year. This is 167.97 percentage points lower than the US Biotechnology industry revenue growth rate of 284.61%. Arbutus Biopharma's revenue in the past year totaled $14.61 million.

How much does Arbutus Biopharma make in a year?

Arbutus Biopharma's revenue by year for the past five years is:
  • Arbutus Biopharma's revenue for the twelve months ending Dec 31, 2024 was $6.17 million, a 65.98% decrease year over year.
  • Arbutus Biopharma's annual revenue for Dec 31, 2023 was $18.14 million, a 53.51% decrease from 2022.
  • Arbutus Biopharma's annual revenue for 2022 was $39.02 million, a 255.11% increase from 2021.
  • Arbutus Biopharma's annual revenue for 2021 was $10.99 million, a 58.92% increase from 2020.
  • Arbutus Biopharma's annual revenue for 2020 was $6.91 million, a 15.02% increase from 2019.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.